Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.76 -0.3%	$0.61	$0.38 ▼ $269.28	$8.73M	0.57	1.03 million shs	90,863 shs
AKBA Akebia Therapeutics	$3.61 -1.0%	$3.02	$0.91 ▼ $4.08	$954.70M	0.84	3.14 million shs	3.01 million shs
ANL Adlai Nortye	$1.60 +8.6%	$1.77	$1.10 ▼ $4.10	$58.89M	-0.84	12,167 shs	369 shs
SIGA Siga Technologies	$6.48 -0.6%	$6.07	$4.95 ▼ $12.83	$465.43M	0.93	718,578 shs	147,673 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	+0.13%	+7.44%	+31.94%	+28.03%	-98.99%
AKBA Akebia Therapeutics	-0.27%	0.00%	+20.13%	+90.58%	+256.86%
ANL Adlai Nortye	-10.09%	+4.99%	-20.97%	-31.31%	-54.91%
SIGA Siga Technologies	+0.93%	+5.33%	+8.49%	+18.98%	-14.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	3.4463 of 5 stars	3.5	5.0	0.0	0.6	1.7	1.9
AKBA Akebia Therapeutics	4.2481 of 5 stars	3.6	4.0	4.0	2.1	0.8	0.6
ANL Adlai Nortye	1.962 of 5 stars	3.0	5.0	0.0	2.2	0.0	0.0
SIGA Siga Technologies	1.5274 of 5 stars	0.0	1.0	0.0	2.1	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	47,393.40% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.75	87.24% Upside
ANL Adlai Nortye	2.00	Hold	$9.00	463.91% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
AKBA Akebia Therapeutics	$160.18M	5.91	N/A	N/A	($0.23) per share	-15.67
ANL Adlai Nortye	$5M	11.78	N/A	N/A	$0.69 per share	2.31
SIGA Siga Technologies	$138.72M	3.34	$0.84 per share	7.72	$3.02 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	$298.12	4.29	N/A	N/A	N/A	N/A	-994.63%	8/11/2025 (Estimated)
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/8/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.72	5.18	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)

Latest ANL, AKBA, SIGA, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Latest ANL, AKBA, SIGA, and AEON Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA Siga Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
AKBA Akebia Therapeutics	1.89	2.23	2.02
ANL Adlai Nortye	0.02	1.41	1.41
SIGA Siga Technologies	N/A	8.40	6.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
AKBA Akebia Therapeutics	33.92%
ANL Adlai Nortye	35.21%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
AKBA Akebia Therapeutics	3.00%
ANL Adlai Nortye	N/A
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

Investors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

June 26, 2025 | marketbeat.com

New nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactors

June 25, 2025 | msn.com

General Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod Technology

June 24, 2025 | indystar.comI

Here's Why Siga Technologies Inc. (SIGA) Fell More Than Broader Market

June 20, 2025 | zacks.com

Undiscovered Gems In US Market Including SIGA Technologies And 2 Other Small Caps

June 17, 2025 | finance.yahoo.com

Bank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

June 16, 2025 | marketbeat.com

Why Siga Technologies Inc. (SIGA) Dipped More Than Broader Market Today

June 13, 2025 | zacks.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.

June 13, 2025 | marketbeat.com

Traders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)

June 12, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Short Interest Down 12.5% in May

June 4, 2025 | marketbeat.com

We Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster Earnings

May 16, 2025 | finance.yahoo.com

Undiscovered Gems in the US Market for May 2025

May 15, 2025 | finance.yahoo.com

SIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)

May 10, 2025 | finance.yahoo.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call Transcript

May 9, 2025 | msn.com

SIGA Reports Financial Results for Three Months Ended March 31, 2025

May 8, 2025 | globenewswire.com

Calculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

May 2, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for Investors

May 1, 2025 | zacks.com

SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results

May 1, 2025 | globenewswire.com

Chiliz joins SIGA to help drive integrity in sport

April 30, 2025 | en.as.comE

Why SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%

April 29, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
By Leo Miller | June 10, 2025
View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.76 0.00 (-0.26%)

As of 01:01 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Akebia Therapeutics NASDAQ:AKBA

$3.60 -0.04 (-0.96%)

As of 01:03 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$1.60 +0.13 (+8.57%)

As of 11:58 AM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Siga Technologies NASDAQ:SIGA

$6.48 -0.04 (-0.60%)

As of 01:02 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time